4BASEBIO PLC 5 February 2024
4basebio plc
(“4babsebio” or the "Company")
Directors’ Dealings
Cambridge, UK, 5 February 2024 - 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, thermostable nucleic acid delivery platform, announces that, further to its announcement of 2 February 2024, directors of the Company have sold shares in order to pay for options exercised as follows:
| Name | Number of Shares Sold | Sale price per share (p) | Shareholding Following Sale | Shareholding as a Percentage of Issued Share Capital |
| Heikki Lanckriet | 45,322 | 660p | 1,418,994 | 11.09% |
| David Roth | 38,292 | 660p | 457,708 | 3.58% |
The calculations above are based on an issued share capital of the Company of 12,796,208 ordinary shares.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.
For further enquiries, please contact:
| 4basebio PLC | +44 (0)12 2396 7943 |
| Heikki Lanckriet, CEO | |
| Cairn Financial Advisers LLP (Nominated Adviser) | +44 (0)20 7213 0880 |
| Jo Turner / Sandy Jamieson | |
| Cavendish Capital Markets Limited (Broker) | +44 (0)20 7220 0500 |
| Geoff Nash/Charlie Beeson |
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name |
| |||
| 2 | Reason for notification | ||||
| a. | Position/Status |
| |||
| b. | Initial notification/Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | 4basebio plc | |||
| b. | LEI | 213800E2DX9EAIUNCB30 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary Shares ISIN: GB00BMCLYF79 | |||
| b. | Nature of the transaction | Sale of Ordinary Shares | |||
| Price(s) per share (p) | Volume(s) | ||||
| 45,322 38,292 | ||||
| d. | Aggregated information
|
| |||
| e. | Date of the transaction | 2/2/2024 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
